PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel

Initial results from large study that tracked CIPN in more than 1,100 patients treated for breast cancer with a taxane show a pattern of clinically meaningful, persistent sensory and motor symptoms, with more severe symptoms with paclitaxel than docetaxel

2023-06-01
(Press-News.org)

Chemotherapy-induced peripheral neuropathy (CIPN) – nerve pain, tingling, or numbness in the hands or feet – is a common side effect of certain cancer treatments, including two drugs frequently used to treat cancer – the taxanes paclitaxel and docetaxel. Initial results from a large study that tracked CIPN in more than 1,100 patients treated for breast cancer with a taxane show a pattern of clinically meaningful, persistent sensory and motor symptoms, with patients experiencing more severe symptoms with paclitaxel than with docetaxel.

These initial results from the SWOG S1714 clinical trial are being reported in an oral presentation at the 2023 annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago on June 5th (abstract 12003). 

Senior author on the abstract Michael J. Fisch, MD, clinical professor at the University of Texas MD Anderson Cancer Center, said “These results from SWOG S1714 are highly relevant because taxanes such as paclitaxel and docetaxel are integral to our treatment of breast cancer. Peripheral neuropathy due to these drugs is familiar but poorly understood. Importantly, neuropathy symptoms were assessed not only by clinicians but also from the patient’s perspective using the CIPN-20 questionnaire.”

S1714 was a prospective observational cohort study to develop a predictive model of taxane-induced peripheral neuropathy in patients with cancer. It enrolled 1,336 patients with either non-small cell lung cancer, breast cancer, or ovarian/fallopian tube cancer who were receiving treatment with paclitaxel or docetaxel. The ASCO abstract reports data from 1,103 participants with breast cancer followed through their first 24 weeks after trial registration.

All patients enrolled on S1714 were evaluated for symptoms of peripheral neuropathy before treatment and again after 4, 8, 12, 24, 52, 104, and 156 weeks from registration. Patients underwent neurosensory testing and functional testing, and clinicians assessed them for CIPN symptoms using the NCI’s Common Terminology Criteria for Adverse Events (CTCAE).

Patients also completed their own self-assessment using an established patient-reported outcome measure, the EORTC QLQ-CIPN20 questionnaire, which scores symptoms overall on a 100-point scale, with higher scores indicating worse symptoms. Multiple studies have found that patients with CIPN experience a 7-10 point increase in their sensory subscale score on this survey. S1714 defined a sensory subscale score increase of 8 points or more as a clinically meaningful worsening of the symptom. 

Through 24 weeks, patients with breast cancer enrolled to S1714 experienced clinically meaningful and persistent sensory and motor symptoms. Over 40 percent of patients receiving paclitaxel or docetaxel experienced a clinically meaningful increase in the CIPN-20 sensory subscore at 24 weeks. At nearly every timepoint through 24 weeks, patients treated with paclitaxel had more sensory neuropathy than patients treated with docetaxel.

Paclitaxel and docetaxel are standard treatments for early-stage breast cancer. Both can lead to CIPN, but differences in symptoms caused by the two drugs have not been well described previously.

Currently, factors such as a patient’s age, preexisting neuropathy, and previous paclitaxel exposure are considered to be strong predictors of CIPN. The larger goal of the SWOG S1714 study is to develop a risk prediction model that can help doctors individualize patient care using common clinical factors. In addition, the S1714 team collected blood samples from all enrolled patients at multiple timepoints, and they are now analyzing a range of biomarkers to identify additional predictors. The team will also assess the effects of dosing frequency and dosing modifications on CIPN symptoms.

“There is a need to better understand CIPN, as it has the potential to impact patient outcomes and quality of life,” said Meghna S. Trivedi, MD, MS, of the Columbia University Herbert Irving Comprehensive Cancer Center. Dr. Trivedi leads the study and will present the results at the ASCO meeting. 

“S1714 was designed to collect the data and specimens to allow us to better characterize CIPN so that we can not only individualize cancer treatment strategies but also identify novel interventions for the prevention and treatment of CIPN,” Dr. Trivedi added.
 

Study S1714 is supported by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), led by SWOG, and conducted by the NIH-funded NCI Community Oncology Research Program (NCORP).

S1714 was funded by the NIH/NCI through grants UG1CA189974 and R37CA277043 and in part by The Hope Foundation for Cancer Research.

In addition to Drs. Trivedi and Fisch, the S1714 study team included Joseph M. Unger, SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center; Dawn L. Hershman, Columbia University; Amy Darke, SWOG Statistics and Data Management Center and Fred Hutchinson Cancer Center; Daniel Louis Hertz, University of Michigan; Thomas Brannagan, Columbia University Medical Center; Stephanie Smith, Lewis Cancer & Research Pavilion at St. Joseph's Candler/Georgia NCORP; Bryan P. Schneider, Indiana University; William Johnson Irvin Jr., Bon Secours Cancer Institute at St. Francis; Amanda Redden Hathaway, University Cancer & Blood Center; Amy C. Vander Woude, Cancer & Hematology Centers of Western Michigan; Vinay K. Gudena, Cone Health Cancer Center; and Norah Lynn Henry, University of Michigan Rogel Cancer Center.
 

SWOG Cancer Research Network is part of the National Cancer Institute's National Clinical Trials Network and the NCI Community Oncology Research Program and is part of the oldest and largest publicly funded cancer research network in the nation. SWOG has more than 18,000 members in 45 states and nine foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org, and follow us on Twitter at @SWOG.
 

Reference:
“Chemotherapy Induced Peripheral Neuropathy (CIPN) due to Paclitaxel versus Docetaxel in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481).” ASCO 2023 oral presentation, June 5, 2023, 8 – 11 am CT (abstract 12003).

END



ELSE PRESS RELEASES FROM THIS DATE:

DOE announces $46 million for commercial fusion energy development

2023-06-01
WASHINGTON, D.C.—The U.S. Department of Energy (DOE) today announced $46 million in funding to eight companies advancing designs and research and development for fusion power plants, representing a major step in President Biden’s commitment to a pilot-scale demonstration of fusion within a decade. Fusion reactions power the stars, and research is underway to make fusion energy production on Earth possible, providing an abundant, inherently safe, non-carbon-emitting energy source for the planet. This funding from the Milestone-Based ...

More than 1 in 6 unvaccinated people report health effects of COVID two years after confirmed infection

2023-06-01
Around 1 in 6 unvaccinated individuals say they are still experiencing health effects of covid-19 up to two years after infection, finds a study from Switzerland published by The BMJ today. The findings show that 17% of participants did not return to normal health and 18% reported covid-19 related symptoms 24 months after initial infection. Most people who have covid-19 recover soon after the initial phase of the disease, but others experience persistent health problems (known as long covid), which can impact quality of life ...

Improving emergency, critical and operative care in low and middle-income countries

2023-06-01
DALLAS and GENEVA, May 31, 2023 — Global efforts to improve emergency, critical and operative care for universal health coverage and protection from health emergencies were announced at the 76th World Health Assembly in Geneva, Switzerland. With the support of its partners the American Heart Association and the Laerdal Foundation, the World Health Organization (WHO), announced an initiative based on a new acute care resolution that was approved at this year’s World Health Assembly, the decision-making body of WHO. Nearly 30 million deaths are due to emergency conditions each year, contributing to half of global deaths. The acute ...

Huntsman Cancer Institute May research highlights

Huntsman Cancer Institute May research highlights
2023-06-01
Huntsman Cancer Institute research highlights shine the spotlight on new discoveries and cutting-edge cancer research. This past month, researchers found a better treatment practice for patients who have melanoma. They also created a model for adrenocortical carcinoma, a rare cancer that originates in the outer portion of the adrenal gland. Learn more about a new brain cancer medication being fast-tracked for FDA approval and how Huntsman Cancer Institute was selected to conduct clinical trials for cancer patients with HIV. Clinical trial suggests changes to melanoma patient care A study recounting a clinical trial published ...

Postdoctoral research experience gets major boost at Pennington Biomedical

Postdoctoral research experience gets major boost at Pennington Biomedical
2023-06-01
Former Pennington Biomedical Research Center Executive Director Dr. Claude Bouchard and his wife, Monique Chagnon, were celebrated at a luncheon on Tuesday, May 30, for their generous gift to enhance the postdoctoral researcher experience at Pennington Biomedical. As one of the world’s foremost researchers in the genetics of obesity and related diseases, including type 2 diabetes and hypertension, the Bouchard laboratory has trained about 40 postdoctoral researchers throughout his career. “I became very conscious that postdocs are critical to the success of the scientific research enterprise. They work hard, they ...

New liver dialysis device shows potential to resolve liver failure in patients with acute-on-chronic liver failure

New liver dialysis device shows potential to resolve liver failure in patients with acute-on-chronic liver failure
2023-06-01
Amsterdam, June 1, 2023 – Acute-on-chronic liver failure (ACLF) occurs in 30% of hospitalized cirrhosis patients, leading to over one million deaths worldwide each year. Currently the only potential treatment for this condition is liver transplantation, which is available to very few patients. A first-in-human randomized controlled clinical trial using DIALIVE, a novel liver dialysis device, demonstrated its potential as a disease-modifying therapy and resolved liver failure significantly faster and in a greater proportion of patients ...

Liver dialysis device proved safe and effective for treating severe liver failure

2023-06-01
The first successful in-patient trial of liver dialysis* has been completed by researchers from UCL, the Royal Free Hospital, UCL spin-out Yaqrit and their collaborators. The DIALIVE device, invented by researchers at UCL’s Institute for Liver and Digestive Health, was found to be safe and was associated with substantial improvement in the severity of symptoms and organ function in a greater proportion of patients with acute-on-chronic liver failure (ACLF), when compared with patients receiving standard of care. The next step will be a larger clinical trial, which if successful could see DIALIVE approved for clinical use within the next three years. Worldwide, it is estimated that there ...

Xrays reveal ancient secrets about our prehistoric world this World Dinosaur Day

2023-06-01
Researchers are shedding light on our ancient prehistoric world using state-of-the art Xray technology. This World Dinosaur Day, scientists are sharing the bones which lay beneath the Harbury Icthyosau – providing clues to dinosaur anatomy, physiology and evolution. The University's of Warwick’s Centre for Imaging, Metrology and Additive Technologies (CiMAT) group at WMG has employed its cutting-edge equipment to explore the anatomy and biology of the Harbury Icthyosaur, a large marine reptile which lived on the Earth hundreds of millions of years ...

Phototherapy device has potential to be a novel treatment for sleep complaints

Phototherapy device has potential to be a novel treatment for sleep complaints
2023-05-31
DARIEN, IL – Wearing a phototherapy device that emits near-infrared light is associated with potential therapeutic benefits for sleep and daytime functioning, according to a new study to be presented at the SLEEP 2023 annual meeting. Results show that self-reported, sleep-related symptoms improved after three weeks of treatment. Participants in the active treatment group reported experiencing better sleep quality, feeling more refreshed and relaxed, and functioning better during the day. “This novel phototherapy device — while ...

UC Irvine-led interdisciplinary team delves into a heated debate about humidity

2023-05-31
Irvine, Calif., May 31, 2023 – As climate change increases the severity, frequency and duration of heat waves around the world, researchers at the University of California, Irvine and other institutions are sounding an alarm about what they consider to be an added threat to human health: humidity. Heat extremes increase the risk of illness and death, with the worst outcomes among people who are older, have chronic diseases, live in hot climates and are socioeconomically disadvantaged. In addition, humidity causes heat stress by making it harder for bodies to cool, but medical and public health experts still disagree about ...

LAST 30 PRESS RELEASES:

Genetic causes of cerebral palsy uncovered through whole-genome sequencing

Modesty and boastfulness – perception depends on usual performance

Do sweeteners increase your appetite? New evidence from randomised controlled trial says no 

Women with obesity do not need to gain weight during pregnancy, new study suggests

Individuals with multiple sclerosis face substantially greater risk of hospitalisation and death from COVID-19, despite high rates of vaccination

Study shows obesity in childhood associated with a more than doubling of risk of developing multiple sclerosis in early adulthood

Rice Emerging Scholars Program receives $2.5M NSF grant to boost STEM education

Virtual rehabilitation provides benefits for stroke recovery

Generative AI develops potential new drugs for antibiotic-resistant bacteria

Biofuels could help island nations survive a global catastrophe, study suggests

NJIT research team discovering how fluids behave in nanopores with NSF grant

New study shows association of historical housing discrimination and shortfalls in colon cancer treatment

Social media use may help to empower plastic surgery patients

Q&A: How to train AI when you don't have enough data

Wayne State University researchers uncover potential treatment targets for Zika virus-related eye abnormalities

Discovering Van Gogh in the wild: scientists unveil a new gecko species

Small birds spice up the already diverse diet of spotted hyenas in Namibia

Imaging detects transient “hypoxic pockets” in the mouse brain

Dissolved organic matter could be used to track and improve the health of freshwaters

Indoor air quality standards in public buildings would boost health and economy, say international experts

Positive associations between premenstrual disorders and perinatal depression

New imaging method illuminates oxygen's journey in the brain

Researchers discover key gene for toxic alkaloid in barley

New approach to monitoring freshwater quality can identify sources of pollution, and predict their effects

Bidirectional link between premenstrual disorders and perinatal depression

Cell division quality control ‘stopwatch’ uncovered

Vaccine protects cattle from bovine tuberculosis, may eliminate disease

Andrew Siemion to receive the SETI Institute’s 2024 Drake Award

New study shows how the Crimean-Congo hemorrhagic fever virus enters our cells

Neoadjuvant chemotherapy proves effective for locally advanced penile squamous cell carcinoma

[Press-News.org] Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel
Initial results from large study that tracked CIPN in more than 1,100 patients treated for breast cancer with a taxane show a pattern of clinically meaningful, persistent sensory and motor symptoms, with more severe symptoms with paclitaxel than docetaxel